PRIMAVERA: a phase 1/2 trial testing AZD3470 in people with relapsed or refractory lymphoma

This trial aims to test the treatment AZD3470 alone and in combination with anticancer agents in people with lymphoma which has come back (relapsed) or not responded (refractory) to treatment.

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT06137144

Trial aim and background  

The aim of this trial is to test the safety and effectiveness of AZD3470 when given alone, or in combination with other anticancer treatments in people with relapsed or refractory lymphoma.

Some of this trial is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future. 

Who can enter 

These are a number of cohorts in this trial. You might be eligible if you have relapsed or refractory classical Hodgkin lymphoma, peripheral T-cell lymphoma (PTCL), anaplastic large cell lymphoma (ALCL) or angioimmunoblastic T-cell lymphoma (AITL).

Locations 

Recruitment for this trial is taking place in the following UK locations: 

  • Manchester
  • Oxford

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT06137144

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.